Daniel Brook

Daniel Brook

Partner
London

Email [email protected]​hoganlovells.com

Phone +44 20 7296 5484

Fax +44 20 7296 2001

LanguagesEnglish

Practice groupIntellectual Property, Media, and Technology

"Daniel Brook is ‘technically very competent’ and ‘gets the ins and outs of even the most complex piece of patent litigation’".

Legal 500, 2018

Daniel is a patent litigator in the UK.  He acts for clients such as MSD, Lilly, Amgen and BMS.  Recent key cases include Actavis v Lilly (Supreme Court), Schutz v Werit (Supreme Court), and BMS v Teva (availability of interim injunctions).

He has experience with each of the major patent jurisdictions in Europe. He regularly manages cross border patent litigation for clients on their most important products and has been involved in a number of leading cases.

Daniel is ranked by Chambers UK - 'Clients commend his 'high-quality counselling' and his 'clear, well-structured' communications.', Legal 500, MIP IP Stars, IAM Patent 1000 and Who's Who Legal.

Awards and recognitions

2018

Hot 100
The Lawyer

2017-2018

Intellectual Property: Patent Litigation (UK)
Chambers Global

2018

Impact Case of the Year
Managing Intellectual Property Awards

2014 - 2018

Intellectual Property: Patent Litigation
Chambers UK

2013 - 2018

Pharmaceuticals and biotechnology
Legal 500

2013 - 2018

Intellectual Property
Legal 500

2013 - 2018

IAM Patent 1000

2017 - 2018

Patents
IP Star

2018

Patents
Who's Who Legal

Education and admissions

Education

M.A. Natural Sciences - Chemistry, University of Cambridge, 1999

M.Sci, University of Cambridge, 1999

Memberships

AIPPI Council Member

CIPA

EPLAW

Representative experience

Acting for MSD in relation to patent challenges around its products including simvastatin, lovastatin, alendronate and raltegravir.

Acting for Lilly in relation to patent challenges around its oncology products including pemetrexed (Supreme Court) and gemcitabine.

Acting for BMS in relation to patent challenges around its products, dasatinib, efavirenz and atazanavir.

Acting for a number of electronic clients including HTC, ZTE and BlackBerry on European patent litigation matters.

Loading data